INS and Hypoglycemia: Insulin degludec was proven to allow glycemic control to reach a target of glycated hemoglobin of 7% with a low frequency of nocturnal hypoglycemia, even with substantial variation in dosing intervals, thus allowing dosing schedule flexibility and stability of glycemic control [17].